Predictive value of bone scan index using computer-aided diagnosis system for bone scans in patients receiving first-line hormone therapy for metastatic hormone-sensitive prostate cancer. This is an ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI ...
Credit: Getty Images aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer (HealthDay News) — The automated Bone Scan Index (aBSI) is an independent ...
Single-fraction radiosurgery for the treatment of renal tumors in singular renal units. A phase I dose-escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane ...
An automated bone scan algorithm has shown its value in determining the response to radium-223 (Ra-223) treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), according ...
The U.S. FDA granted 510(k) clearance to Lantheus Holdings Inc.'s artificial intelligence (AI)-enhanced automated bone scan index (aBSI) product for prostate cancer on GE Healthcare's Xeleris platform ...
Researchers have used machine learning to assess bone density scans for calcification in the aorta, the body’s main artery. They say their method could be used to predict future cardiovascular and ...
The automated bone scan index (aBSI) has been validated as an independent predictor of overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC). It is also superior to manual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results